Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

详细信息    查看全文

• 作者：Prof Ludwig Kappos MD^a ; ^{lkappos@uhbs.ch"" rel=""nofollow} ; Prof David Bates MD^b ; Prof Gilles Edan MD^c ; Mefkû ; re Eraksoy MD^d ; Antonio Garcia-Merino MD^e ; Nikolaos Grigoriadis MD^f ; Prof Hans-Peter Hartung MD^g ; Eva Havrdová ; MD^h ; Jan Hillert MDⁱ ; Prof Reinhard Hohlfeld MD^j ; Marcelo Kremenchutzky MD^k ; Prof Olivier Lyon-Caen MD^l ; Ariel Miller MD^m ; Prof Carlo Pozzilli MDⁿ ; Mads Ravnborg MD^o ; Takahiko Saida MD^p ; Prof Christian Sindic MD^q ; Karl Vass MD^r ; Prof David B Clifford MD^s ; Prof Stephen Hauser MD^t ; Eugene O Major PhD^u ; Prof Paul W O'Connor MD^v ; Prof Howard L Weiner MD^w ; Prof Michel Clanet MD^x ; Prof Ralf Gold MD^y ; Prof Hans H Hirsch MD^a ; Prof Ernst-Wilhelm Radü ; MD^a ; Prof Per Soelberg Sø ; rensen MD^z ; John King MD^aa
• 刊名：Lancet Neurology
• 出版年：2011
• 出版时间：August 2011
• 年：2011
• 卷：10
• 期：8
• 页码：745-758
• 全文大小：414 K

文摘

Summary

Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.